Madhu Midathada, MD
Hematology & Oncology · Lincoln, NENPI 1265511034
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,888 of the $23,942 with a category attached, or 91.4%. 41 manufacturers reported payments, led by AstraZeneca at 45.4% of the total. 2025 is the largest year on record at $14,748, more than ten times the $109 reported in 2019.
Across 92 payments — averaging $260.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- AbbVie$4K
- E.r. Squibb & Sons, L.L.C.$3K
- Beigene USA, Inc.$2K
- Janssen Scientific Affairs, LLC$1K
- Daiichi Sankyo Inc.$685
- plus $2K from 35 others
Across 114 payments — averaging $9719.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$943K
- Sanofi US Services Inc.$79K
- Roche Products Limited$49K
- Pharmacyclics LLC, An Abbvie Company$12K
- Amgen$12K
- Eli Lilly$10K
- plus $3K from 1 others
What the payments were for
- Consulting fees$21,88891%
- Travel & lodging$6303%
- Food & beverage$1,1225%
- Education$3041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $10,866 |
| AbbVie | 11 | $4,380 |
| E.r. Squibb & Sons, L.L.C. | 2 | $2,502 |
| Beigene USA, Inc. | 3 | $2,483 |
| Janssen Scientific Affairs, LLC | 1 | $1,388 |
| Daiichi Sankyo Inc. | 3 | $685 |
| Beigene, Ltd. | 1 | $525 |
| Pfizer | 6 | $112 |
| Incyte Corporation | 1 | $100 |
| Genentech USA, Inc. | 3 | $83 |
| GSK | 4 | $68 |
| Gilead(2 entities) | 4 | $63 |
| Astellas Pharma US Inc | 2 | $48 |
| Array Biopharma Inc | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $39 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $39 |
| Seagen Inc. | 2 | $38 |
| Bristol Myers Squibb | 2 | $36 |
| Merck | 2 | $34 |
| Novartis | 2 | $31 |
| Johnson & Johnson | 2 | $31 |
| Tersera Therapeutics LLC | 1 | $31 |
| Lilly USA, LLC | 2 | $28 |
| Sanofi | 1 | $24 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| Aurobindo Pharma USA, Inc. | 1 | $22 |
| Sobi, Inc | 1 | $21 |
| Clovis Oncology, Inc. | 2 | $20 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| EMD Serono, Inc. | 1 | $19 |
| Beone Medicines USA, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Mirati Therapeutics, Inc. | 1 | $14 |
| Partner Therapeutics, Inc. | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Medtronic | 1 | $12 |
| Acrotech Biopharma Inc. | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
| Foundation Medicine, Inc. | 1 | $11 |
| Veran Medical Technologies, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,942 in reported general payments places this provider in the 80th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 37 | $463,646 |
| KisqaliRibociclib Succinate | 32 | $457,246 |
| RevlimidLenalidomide | 24 | $419,409 |
| ImbruvicaIbrutinib | 19 | $290,810 |
| IbrancePalbociclib | 18 | $268,255 |
| BrukinsaZanubrutinib | 18 | $253,469 |
| VenclextaVenetoclax | 17 | $208,251 |
| EliquisApixaban | 25 | $15,337 |
| XareltoRivaroxaban | 17 | $11,921 |
| Anastrozole | 297 | $4,807 |
| Abiraterone Acetate | 12 | $3,510 |
| Exemestane | 21 | $1,463 |
| Tamoxifen Citrate | 53 | $1,371 |
| Letrozole | 77 | $1,136 |
| Mercaptopurine | 11 | $1,112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $31 | $457,24632 claims |
| Bristol Myers SquibbRevlimid | $36 | $419,40924 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $39 | $290,81019 claims |
| PfizerIbrance, Eliquis | $112 | $283,59243 claims |
| Beigene USA, Inc.Brukinsa | $2,483 | $253,46918 claims |
| AbbVieVenclexta | $4,380 | $208,25117 claims |
| Johnson & JohnsonXarelto | $31 | $11,92117 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,388 | $3,51012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Lincoln
- Steven DunderLincoln$20K
- Kailash MosalpuriaLincoln$17K
- Nathan GreenLincoln$10K
- Melissa CetakLincoln$6K
- Eric AveryLincoln$6K
- Wallace PetersonLincoln$5K
- Amanda BauerLincoln$5K
- Joni TilfordLincoln$4K
- Kathleen TonkinLincoln$4K
- Scott McHamLincoln$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.